Leonard Lauder, former CEO of beauty empire Estée Lauder, dies at 92

Leonard Lauder, CEO emeritus of the multibillion-dollar Estée Lauder beauty empire founded by his parents and named after his mother, has died.
He was 92.
The Estée Lauder Companies Inc. announced his death Sunday 'with deep sadness' and said Lauder, the eldest son of Estée and Joseph Lauder, had died at home 'surrounded by family.'
The New York City native graduated from the Bronx High School of Science and studied business at Columbia University, among other prominent schools, the company said. After formally joining the family business in 1958, he expanded the single brand 'handful of products' into a global beauty empire during six decades at the company. He served as president from 1972-1995, as CEO from 1982-1999, and as chairman from 1995 through June 2009, and was 'deeply involved' in company acquisition strategy until his death. The 'true visionary, fearless leader, and cherished friend to so many' was 'the beacon of our company and the north star of an entire industry,' the company said.
'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William Lauder, his son and the current chairman of Estée Lauder's board of directors. 'Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous.'
Lauder was known as much for his philanthropy as for his business acumen, and championed health causes such as Alzheimer's disease and breast cancer. He pledged $1 billion in Cubist works to the Metropolitan Museum of Art, donated $125 million to the University of Pennsylvania School of Nursing and gave $10 million to Hunter College's nursing school in New York City. Lauder helped his late wife Evelyn Lauder launch the famous Pink Ribbon campaign, an awareness initiative of the Breast Cancer Research Foundation, which she founded in 1993.
In 1998, Lauder and his brother Ronald Lauder co-founded the Alzheimer's Drug Discovery Foundation, which 'reshaped the Alzheimer's research landscape,' ADDF co-founder and chief science officer Dr. Howard Fillit said, adding that 'Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's.'
___________

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

3 days ago

• Yahoo

Walmart (NYSE:WMT) Partners With Soda Health To Enhance Member Wellness Through Retail Insights

Walmart recently announced a collaboration with Soda Health to launch the Walmart Everyday Health Signals Program, aiming to enhance wellness for Medicare Advantage and Medicaid members. Over the last quarter, Walmart's share price increased by 9%, reflecting the company's efforts to innovate in personalized healthcare solutions alongside a general upward market trend. During the period, key developments, like the national launch of PurSteam Steam Station Max, along with the introduction of sustainable beverage supplies and in-store expansion initiatives, added momentum to Walmart's performance. Meanwhile, legal matters like the Zest Labs verdict and strategic buybacks likely moderated any potential headwinds. We've discovered 2 weaknesses for Walmart that you should be aware of before investing here. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The collaboration between Walmart and Soda Health to launch the Everyday Health Signals Program could enhance its focus on personalized healthcare, aligning with its expansion into higher-margin ventures like membership, marketplace, and advertising. These initiatives may positively influence Walmart's revenue and earnings forecasts by potentially boosting operational efficiency and customer engagement, though execution risks remain. In terms of share price movement, the recent increase of 9% over the last quarter appears consistent with these strategic moves and broader market trends. Walmart's shares have achieved a total return of 150.80% over the past five years, showcasing impressive long-term growth. In contrast, over the last year, Walmart's performance slightly lagged behind the US Consumer Retailing industry, which returned an average of 7.80%, with Walmart's one-year return being 6.80%. This suggests that while long-term growth has been robust, recent performance may reflect current operational challenges or competitive pressures within the industry. The analyst consensus price target for Walmart is US$107.01, representing a 7.90% potential upside from the current share price of US$98.55. Given the company's recent achievements and investments, along with the anticipated enhancements in operational efficiency and revenue streams, the divergence between the current share price and the target may indicate market expectations of continued growth, albeit tempered by existing risks and market conditions. It remains important for investors to evaluate these factors and their alignment with personal investment strategies. Explore historical data to track Walmart's performance over time in our past results report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:WMT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Business Wire

3 days ago

• Business Wire

Atalanta Therapeutics Announces Leadership Transitions

BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today that Joanne Kotz has been named Chief Executive Officer and a member of the Board of Directors, succeeding Alicia Secor, who has stepped down as part of a planned transition to pursue other opportunities. The company also announced the appointment of Douglas Pagán as Chief Financial Officer & Chief Operating Officer, succeeding Jeffrey Young. Additionally, Bob D. Brown, an industry veteran with extensive RNAi drug discovery and development experience, has joined the company's Scientific Advisory Board to advise as the company advances its innovative pipeline into the clinic. "I want to thank Alicia for her extraordinary leadership of the company from formation to the cusp of entry into the clinic, as well as her continued role as an advisor through this transition,' said Dr. Stephen Knight, President and Senior Managing Partner of F-Prime and a member of the Atalanta Board of Directors. 'We are delighted to have Joanne lead Atalanta's next stage. Joanne is an accomplished leader who has demonstrated the ability to advance innovative platforms and pipelines through the transition to clinical stage, and has optimized company value creation through strong financings, partnerships and strategic transactions.' 'I'm thrilled to be joining Atalanta, which is pioneering the effort to bring RNAi therapies to patients living with devastating neurological diseases,' said Dr. Kotz. 'I am passionately committed to Atalanta's mission to deliver life-transforming therapies to patients and look forward to working with the team to transition our first programs into the clinic as we work to realize the full therapeutic potential of Atalanta's innovative di-siRNA platform.' 'Over the past six years we've made incredible scientific progress at Atalanta. I'm proud of all that we've been able to accomplish together and thank the Board and team for their support and dedication to our mission,' said Ms. Secor. 'The transition from research to clinical stage is a critical time for any biotech, and Joanne's leadership and experience is ideally suited to guide Atalanta's continued progress towards our mission of delivering RNAi medicines to patients living with severe neurological diseases.' Dr. Kotz brings to Atalanta extensive executive experience, including most recently as cofounder and CEO of Jnana Therapeutics. She led the company from an early discovery platform stage through the transition to clinical stage. Jnana was acquired by Otsuka Pharmaceutical in 2024 for ~$1 billion following the demonstration of positive clinical proof of concept for the company's lead rare disease program. Prior to Jnana, Dr. Kotz held leadership roles at FBRI, F-Prime Capital's initiative to enable therapeutic breakthroughs in Alzheimer's disease and related brain disorders, and at the Broad Institute. She is a member of the Board of Directors of the Chordoma Foundation. Dr. Kotz received her Ph.D. in chemistry from the University of California, Berkeley and a B.S. in chemistry from the University of Florida. She conducted postdoctoral research at Genentech and at the Necker Children's Hospital in Paris. Mr. Pagán brings to Atalanta more than two decades of experience in finance, investor relations, and capital formation across both public and venture-backed biopharmaceutical companies. Prior to joining Atalanta, he served as Chief Financial Officer and Chief Operating Officer at Jnana Therapeutics, where he was instrumental in securing the company's $107 million Series C financing heading into the clinic, and the subsequent ~$1 billion acquisition by Otsuka Pharmaceutical. Prior to Jnana, Mr. Pagán was Chief Financial Officer at the RNAi company Dicerna Pharmaceuticals, where he oversaw the 2021 sale of the company to Novo Nordisk for $3.3 billion. He has previously held leadership roles at Acceleron and Biogen and has served on the Board of Directors of the biotech companies Ziopharm Oncology and Timberlyne Therapeutics. Mr. Pagán holds an MBA from Columbia Business School and a BSE in chemical engineering from Princeton University. Dr. Brown brings more than 30 years of experience in RNAi and oligonucleotide research and development, including from discovery through drug approval and across a wide range of clinical indications and regulatory jurisdictions. Most recently, Dr. Brown served as Chief Scientific Officer and Executive Vice President of R&D at Dicerna Pharmaceuticals, an RNAi-focused therapeutics company that was acquired by Novo Nordisk. At Novo, he served as President and Head of the Dicerna Transformation Research Unit and SVP. Prior to Dicerna, Dr. Brown held various R&D leadership positions at Genta, a clinical-stage antisense oligonucleotide therapeutics company, and previously was a co-founder of Oasis Biosciences, which was acquired by Gen-Probe. Dr. Brown earned a Ph.D. in molecular biology from the University of California, Berkeley and B.S. degrees in chemistry and biology from the University of Washington, Seattle. About Atalanta Therapeutics Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta's unique platform of divalent small interfering RNA (di-siRNA) is designed to enable durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington's disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass. For more information, visit

Yahoo

4 days ago

• Yahoo

Estee Lauder (EL), Consumer Stocks Jump 10.8%

The Estée Lauder Companies Inc. (NYSE:EL) is one of the . Estee Lauder jumped by 10.82 percent on Monday to finish at $74.59 apiece, tracking a generally optimistic market environment following the United States' trade deal progress with two of its trading partners. The Estée Lauder Companies Inc. (NYSE:EL) rallied in line with the recovery of consumer stocks, one of the sectors most sensitive to shifts in the global trade environment. In other news, The Estée Lauder Companies Inc. (NYSE:EL) announced the passing of its chairman emeritus, Leonard A. Lauder, at age 92. A close-up of a makeup artist carefully applying Makeup Products to an clients face. Leonard is the son of the company's founders, Estee and Joseph. He finished studies at the Columbia University's Graduate School of Business and served as lieutenant in the US Navy and as a Navy reservist. He formally joined Estée Lauder in 1958, became its president from 1972 to 1995 and as CEO from 1982 to 1999. He was named chairman in 1995 and served in that role through June 2009. While we acknowledge the potential of EL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.